PRTA Prothena Corporation plc
USHealthcareAs of 2026-10-08
Why PRTA matters now
Prothena Corporation plc (PRTA) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.61 with +1.53% on the session and $450.8M in market capitalization; recent performance reads 1-month -1.54% and YTD -6.49%.
The latest financial table shown here is Q1 2026, with revenue of $51.1M, net income of $32.7M, and EPS of $0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.4%.
The latest indexable market news headline is "4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $19.00; recent insider activity includes SCULLY WILLIAM P filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.53
P/S
8.07
EV/EBITDA
-1.95
DCF Value
$3.52
FCF Yield
-17.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
46.8%
Operating Margin
-217.9%
Net Margin
-260.9%
ROE
-49.9%
ROA
-43.2%
ROIC
-39.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $51.1M | $32.7M | $0.60 |
| Q4 2025 | $21.0K | $-21.6M | $-0.40 |
| FY 2025 | $9.7M | $-244.1M | $-4.53 |
| Q3 2025 | $2.4M | $-36.5M | $-0.68 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$19.00
Target (Median)
$19.00
Target Range
$19.00 - $19.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.32
Established in 2012 and headquartered in Dublin, Ireland, Prothena Corporation plc functions as a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapeutic solutions for critical, life-threatening conditions, primarily within the United States. The company's pipeline features several key programs: Birtamimab, an investigational humanized antibody, is currently undergoing Phase III clinical trials for the treatment of AL amyloidosis. Prasinezumab, a humanized monoclonal antibody, is progressing through Phase IIb trials for Parkinson's disease. Prothena has also completed Phase I clinical trials for PRX004, indicated for Transthyretin amyloidosis, and is advancing PRX005 through Phase I for Alzheimer's disease. In its earlier-stage development, Prothena is exploring PRX012 for Alzheimer's disease, alongside a dual Aß-Tau vaccine designed for both the treatment and prevention of Alzheimer's disease. Prothena maintains strategic partnerships, including a comprehensive license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. for antibodies targeting alpha-synuclein. The company also collaborates with Bristol-Myers Squibb on antibody development.